The molecular perspective: major histocompatibility complex

Email citation

Your saved search

Your RSS Feed

. 2005 Mar;23(3):454-5.

doi: 10.1634/stemcells.FCM2.

Affiliations

David S Goodsell. Stem Cells. 2005 Mar.

. 2005 Mar;23(3):454-5.

doi: 10.1634/stemcells.FCM2.

¹ The Scripps Research Institute, Department of Molecular Biology, La Jolla, California 92037, USA. goodsell@scripps.edu

No abstract available

Similar articles

The major histocompatibility complex determines susceptibility to cytotoxic T cells directed against minor histocompatibility antigens. 1975.
Bevan MJ. Bevan MJ. J Immunol. 2005 Dec 1;175(11):7069-84. J Immunol. 2005. PMID: 16301608 No abstract available.
The molecular perspective: major histocompatibility complex.
Goodsell DS. Goodsell DS. Oncologist. 2005 Jan;10(1):80-1. doi: 10.1634/theoncologist.10-1-80. Oncologist. 2005. PMID: 15632255 No abstract available.
T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
Noy R, Eppel M, Haus-Cohen M, Klechevsky E, Mekler O, Michaeli Y, Denkberg G, Reiter Y. Noy R, et al. Expert Rev Anticancer Ther. 2005 Jun;5(3):523-36. doi: 10.1586/14737140.5.3.523. Expert Rev Anticancer Ther. 2005. PMID: 16250828 Review.
[The function of cytotoxic T cells].
Gomard E. Gomard E. Ann Rech Vet. 1992;23(3):295-301. Ann Rech Vet. 1992. PMID: 1416741 Review. French. No abstract available.
Viral interference with MHC class I antigen presentation pathway: the battle continues.
Ambagala AP, Solheim JC, Srikumaran S. Ambagala AP, et al. Vet Immunol Immunopathol. 2005 Aug 15;107(1-2):1-15. doi: 10.1016/j.vetimm.2005.04.006. Vet Immunol Immunopathol. 2005. PMID: 15978672 Review.